Personalized and Precision Medicine Journal
Where Innovations Meets Personalized and Precision Medicine

A Case Report: The Potential Clinical Benefits of Comprehensive Molecular Profiling in an Aggressive NSCL Grade IV

Document Type : Case Study

Authors

Elaheh Aliakbari 1
Mahnaz Saremi 2

1 RayaaGen Accelerator Director, Tehran, Iran.

2 Reference health laboratory, Ministry of health and medical education

https://doi.org/10.22034/pmj.2021.246866
Abstract
We present a Non-Small Cell Lung Cancer Grade IV patient, diagnosed at 46 years of age, with multiple relapse from the diagnosis and demonstrating a poor prognosis after 3 cycles of treatments. A clinical comprehensive genomic profile was performed with the goal of finding potential actionable molecular alterations. The patient showed significant symptomatic and laboratory improvement with a combination chemotherapy determined by the molecular profiling, which would otherwise not have been considered. The mentioned approach was conducted since no other targeted therapies seemed actionable for him.

Keywords

EML4-ALK fusion
TNM stage
Erlotinib
Osimertinib
Next-generation sequencing
Immunohistochemistry
1.Sung H, Ferlay J, Siegel RL, et al. Global Cancer
Statistics 2020: GLOBOCAN Estimates of
Incidence and Mortality Worldwide for 36 Cancers
in 185 Countries. CA Cancer J Clin 2021; 71:209.
2.Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer
Statistics, 2021. CA Cancer J Clin 2021; 71:7.
3.Howlader N, Forjaz G, Mooradian MJ, et al. The
Effect of Advances in Lung-Cancer Treatment on
Population Mortality. N Engl J Med 2020; 383:640.
4.Ann Oncol 2020 Jun;31(6):789-797. doi: 10.1016/j.
annonc.2020.03.293. Epub 2020 Mar 30.
Personalized and Precision Medicine Journal
Volume 6, Issue 22
Original article
Summer 2021
Pages 23-26

  • Receive Date 01 July 2021
  • Revise Date 20 July 2021
  • Accept Date 23 July 2021

Home

Publication Ethics

Guide for Authors

Submit Manuscript

Contact Us